Harvard Bioscience Inc Dossier - Source-backed chat

Harvard Bioscience Inc

HBIONASDAQ

SectorHealth Care

IndustryLife Sciences Tools & Services

Beta (adjusted)1.33

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $8.13Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $37M

Enterprise Value −$13.3M

Shares Outstanding 4.5M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Harvard Bioscience is undergoing a pivotal transition from operational stabilization to high-margin growth. By consolidating its manufacturing footprint (Project Viking) and accelerating the commercialization of its New Product Innovation (NPI) pipeline—including the MeshMEA organoid platform and SoHo telemetry systems—the company is shifting toward a higher-margin, recurring revenue model. Despite recent revenue declines due to softer end-market demand, gross margins are expanding toward the 60% target, and the company's recent 1-for-10 reverse stock split has stabilized its capital structure.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$7.50

Mean target$7.50

High · most bullish analyst$7.50

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$4.50

Transition-related operational disruptions at the Holliston facility delay the consolidation timeline, causing higher-than-expected restructuring charges. Continued soft demand from academic institutions and CROs, combined with NIH budget constraints, limits revenue growth and delays profitability.

Base CaseCentral scenario

$6.00

Harvard Bioscience successfully executes its manufacturing consolidation, achieving $3 million in cost savings in 2027. Full-year 2026 revenue grows at 2%-4% ($88 million to $90 million) with gross margins stabilizing between 58% and 60%, in line with management guidance.

Bull CaseUpside scenario

$6.00

Rapid adoption of the NPI portfolio drives gross margins consistently above 60% and accelerates revenue growth beyond the guided 2%-4% range. Project Viking achieves the targeted $4 million in annual cost savings ahead of schedule, leading to significant adjusted EBITDA expansion and rapid deleveraging.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strategic shift toward higher-margin consumables, software, and translational medicine platforms (currently ~55% recurring revenue).
Project Viking manufacturing consolidation expected to deliver $3 million in annual savings in 2027 and $4 million starting in 2028.
Strong gross margin performance, expanding to 59% in Q1 2026 despite lower revenues.

Key Investment Risks

Exposure to macroeconomic headwinds and softer end-market demand from academic and CRO channels.
Execution risks associated with the relocation of manufacturing operations from Holliston to Minneapolis and European hubs.
High leverage and increased interest expenses following recent debt refinancing.

Thesis Invalidation Triggers

Gross margins falling below 56% due to under-absorption of fixed manufacturing overhead.
Delays in the closure of the Holliston facility beyond Q1 2027, leading to elevated dual-operating costs.
Failure of the NPI portfolio (MeshMEA, SoHo) to gain traction in the biopharma sector, resulting in flat or negative revenue growth.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.